Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

DOI: https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

DOI: https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood (2020) 135 (26): 2375–2387.

DOI: https://doi.org/10.1182/blood.2019003382

Published: 2020

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

DOI: https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Grace Lee, Sheela Karunanithi, Zachary Jackson, David Wald, MD PhD

Blood (2019) 134 (Supplement_1): 3607.

DOI: https://doi.org/10.1182/blood-2019-131947

Published: 2019

Journal Articles

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Ryan N Rys, BSc, BA, Maanasa Venkataraman, MSc, Jibin Zeng, MSc, Koren Kathleen Mann, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1520.

DOI: https://doi.org/10.1182/blood-2019-130602

Published: 2019

Journal Articles

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Christian M. Schuerch, MD PhD, Darci J. Phillips, MD PhD, Salil S. Bhate, MMath, Graham L. Barlow, BA, Steven P Fling, PhD, Nirasha Ramchurren, Robert Pierce, MD, Martin A Cheever, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Garry P. Nolan, PhD

Blood (2019) 134 (Supplement_1): 1521.

DOI: https://doi.org/10.1182/blood-2019-125315

Published: 2019

Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes

Blood (2019) 134 (Supplement_1): 1523.

DOI: https://doi.org/10.1182/blood-2019-123908

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

DOI: https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Katsuyoshi Takata, MD PhD, Lauren C. Chong, MSc, Avinash Thakur, PhD, Tomohiro Aoki, MD PhD, Anja Mottok, MD PhD, Elizabeth Chavez, BSc, Cg RT, Pedro Farinha, MD PhD, Graham W Slack, MD, Pamela Hoodles, Sohrab P Shah, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 1509.

DOI: https://doi.org/10.1182/blood-2019-129730

Published: 2019

Journal Articles

CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to Checkpoint Therapy

Sary El Daker, PhD, Qi Gao, MLS, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 1513.

DOI: https://doi.org/10.1182/blood-2019-130346

Published: 2019

Journal Articles

Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination

Tanaya Shree, MD PhD, Sarah Haebe, MD, Anuja Sathe, PhD, Grady Day, HoJoon Lee, PhD, Debra K. Czerwinski, BA, Susan Grimes, BSc, Hanlee Ji, MD, Ronald Levy, MD

Blood (2019) 134 (Supplement_1): 1479.

DOI: https://doi.org/10.1182/blood-2019-131684

Published: 2019

Journal Articles

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Joshua C Pritchett, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Jose C Villasboas, MD, Andrew L. Feldman, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 1517.

DOI: https://doi.org/10.1182/blood-2019-131145

Published: 2019

Journal Articles

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Alex Vasuthasawat, BS, MS, Reiko E Yamada, Kham R Trinh, Neiki Rokni, Sherie L Morrison, PhD, John M. Timmerman, MD

Blood (2019) 134 (Supplement_1): 1575.

DOI: https://doi.org/10.1182/blood-2019-131890

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Adam Greenbaum, MD PhD, Ajay K. Gopal, MD, Jonathan R. Fromm, MD PhD, A McGarry Houghton, MD

Blood (2019) 134 (Supplement_1): 1518.

DOI: https://doi.org/10.1182/blood-2019-126217

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

DOI: https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Blood (2019) 134 (Supplement_1): 5328.

DOI: https://doi.org/10.1182/blood-2019-122635

Published: 2019

Journal Articles

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Sigrid Strand Skånland, PhD, Bendiksen Henrik, MSc, Andrea Cremaschi, PhD, Deepak Balaji Thimiri Govinda Raj, PhD, Ludvig Andre Munthe, MD PhD, Geir Erland Tjønnfjord, MD PhD, Kjetil Taskén, MD PhD

Blood (2019) 134 (Supplement_1): 5446.

DOI: https://doi.org/10.1182/blood-2019-121890

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

DOI: https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Chloe B. Steen, MSc, Bogdan A. Luca, PhD, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, PhD, Brian Sworder, MD PhD, Farshad Farshidfar, MD PhD, Kiarash Shamardani, BA, David M. Kurtz, MD PhD, Chih Long Liu, PhD, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, June Helen Myklebust, PhD, Maximilian Diehn, MD PhD, Andrew Gentles, PhD, Aaron M Newman, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 655.

DOI: https://doi.org/10.1182/blood-2019-129461

Published: 2019

NARROW

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

CD4 Lymphocytes and T Regulatory Cells Show Distinct Phenotypes in Follicular Lymphoma and Classical Hodgkin Lymphoma Which May Account for Differences in Responses to Checkpoint Therapy

Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only